Atea Pharmaceuticals Q2 2025 slides: HCV program advances with Phase 3 trials underway

3 hours ago 2
Read Entire Article
  1. Homepage
  2. Finance
  3. Atea Pharmaceuticals Q2 2025 slides: HCV program advances with Phase 3 trials underway

Related

DraftKings stock price target raised to $54 from $53 at Jefferies

DraftKings stock price target raised to $54 from $53 at Jeff...

11 minutes ago 0
Cantor Fitzgerald raises Rocket Lab stock price target to $54 on strong Q2

Cantor Fitzgerald raises Rocket Lab stock price target to $5...

11 minutes ago 0
TripAdvisor stock rating reiterated at Outperform by Bernstein SocGen

TripAdvisor stock rating reiterated at Outperform by Bernste...

11 minutes ago 0

Trending

1. manu
2. us open tennis 2025
3. dp world tour
4. weiss memorial hospital
5. elsie hewitt
6. real madrid
7. noaa hurricane
8. ryder cup 2025
9. friday
10. chris janson

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

6 months ago 429
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

7 months ago 207
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

5 months ago 185
Taiwan slightly cuts 2025 GDP growth outlook amid Trump tariffs concern

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

5 months ago 155
Sole mates: Find the perfect shoes for your fitness journey

Sole mates: Find the perfect shoes for your fitness journey

6 months ago 144
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2025. All rights are reserved